Recce Pharma R327G Phase 3 trial reaches key milestone

Recce's R327G Phase 3 trial data now sits with an independent DMC, with a mid-November readout potentially unlocking Indonesian regulatory submission.

• DMC milestone reached: Data from 75 patients in the Phase 3 diabetic foot ulcer infection trial in Indonesia has been submitted to an independent Data Monitoring Committee, expected to meet as soon as mid-November.
• Strong efficacy signal flagged: CEO James Graham says a blinded review by local and international infectious disease experts and a statistician showed an "overwhelming efficacy signal" and a positive safety profile.

Themes, sentiment and reasons are AI-written paraphrases, checked so they never quote an episode. They may contain errors. Not investment advice. Episodes remain the property of their creators.